U ustekinumab yoo-ste-kin-ue-mab (Stelara) Do not confuse Stelara with Aldara, or ustekinumab with infliximab or rituximab. classification PHARMACOTHERAPEUTIC: Monoclonal antibody. CLINICAL: Antipsoriasis agent. Action Strongly binds with cellular components involved in responses to inflammation and immune system, thereby decreasing likelihood of aggravating psoriatic eruptions. Therapeutic Effect: Significantly slows growth, migration of circulating total lymphocytes (predominant in psoriatic lesions). Pharmacokinetics Following subcutaneous injections, clearance is affected by body weight, is not affected by gender or race. Degraded into small peptides and amino acids via catabolic pathways. Serum concentration reaches steady state at 28 wks. Half-life: 10–126 days. Uses Treatment of adults 18 yrs or older with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Treatment of active psoriatic arthritis alone or in combination with methotrexate. Precautions Contraindications: None known. Cautions: History of chronic infection, recurrent infection, active tuberculosis, prior malignancy, renal/hepatic impairment. Avoid use of live vaccines. Lifespan considerations Pregnancy/Lactation: Unknown if distributed in breast milk. Pregnancy Category B. Children: Not indicated for use in this pt population. Elderly: Age-related increased incidence of infection requires cautious use. Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: D H P I Stay updated, free articles. Join our Telegram channel Join Tags: Saunders Nursing Drug Handbook 2015 Mar 8, 2017 | Posted by admin in NURSING | Comments Off on U Full access? Get Clinical Tree
U ustekinumab yoo-ste-kin-ue-mab (Stelara) Do not confuse Stelara with Aldara, or ustekinumab with infliximab or rituximab. classification PHARMACOTHERAPEUTIC: Monoclonal antibody. CLINICAL: Antipsoriasis agent. Action Strongly binds with cellular components involved in responses to inflammation and immune system, thereby decreasing likelihood of aggravating psoriatic eruptions. Therapeutic Effect: Significantly slows growth, migration of circulating total lymphocytes (predominant in psoriatic lesions). Pharmacokinetics Following subcutaneous injections, clearance is affected by body weight, is not affected by gender or race. Degraded into small peptides and amino acids via catabolic pathways. Serum concentration reaches steady state at 28 wks. Half-life: 10–126 days. Uses Treatment of adults 18 yrs or older with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Treatment of active psoriatic arthritis alone or in combination with methotrexate. Precautions Contraindications: None known. Cautions: History of chronic infection, recurrent infection, active tuberculosis, prior malignancy, renal/hepatic impairment. Avoid use of live vaccines. Lifespan considerations Pregnancy/Lactation: Unknown if distributed in breast milk. Pregnancy Category B. Children: Not indicated for use in this pt population. Elderly: Age-related increased incidence of infection requires cautious use. Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: D H P I Stay updated, free articles. Join our Telegram channel Join Tags: Saunders Nursing Drug Handbook 2015 Mar 8, 2017 | Posted by admin in NURSING | Comments Off on U Full access? Get Clinical Tree
classification
Lifespan considerations
